Hypertrust Patient Data Care (HPDC) has launched its extended Hypertrust X-Chain supply chain management solution for Advanced & Personalized Therapies (APT). The company states that it is the first solution that allows biotech and pharmaceutical companies to design, set up, plan, orchestrate, operate and scale APT supply chains with one single system.
The new applications added to Hypertrust X-Chain are:
Hypertrust X-Chain can be implemented as an all-in-one supply chain management solution or flexibly with a focus on specific modules to complement existing system landscapes.
HPDC adds that different modules of Hypertrust X-Chain are combinable, configurable, and scalable to manage end-to-end supply chain needs across all therapy life cycle phases, from the clinical phase up to post-commercialization.
Click to enlarge.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Racial, Social, and Economic Factors Drive Resilience During COVID-19 Pandemic, Study Finds
July 18th 2025The study reveals that resilience varies significantly by race, education, income, and insurance status, highlighting the role of social determinants and systemic inequities in shaping health outcomes.
Thermo Fisher, Sanofi Expand Partnership to Boost Sterile Drug Production
July 16th 2025Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.